FLOT-Induced vs CROSS-Induced Pathological Complete Response

Дата публикации: 01-09-2026 00:00:00

The Perioperative Chemotherapy Compared to Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC) randomized clinical trial, which demonstrated improved survival with perioperative chemotherapy (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT]) compared to preoperative chemoradiotherapy (Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study protocol [CROSS]) for resectable esophageal adenocarcinoma (EAC), caused a paradigm shift in EAC treatment. Despite this shift, recurrences remain high following both regimens and the long-term significance of pathological complete response (pCR) remains unclear.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FLOT vs CROSS in Esophageal Adenocarcinoma	0	6.05	01-09-2026
2	Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer	0	14.35	01-09-2026
3	Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery	0	7.22	10-09-2026
4	Recalibrating “Unresectable” in Pancreatic Cancer	0	12.62	01-09-2026
5	Robot-assisted surgery shows clinical advantages over laparoscopic surgery for gastric cancer	0	8.31	24-08-2026
6	Clinical trial to treat rectal cancer spares major surgery	0	8.49	24-08-2026
7	MAIBE for Patients With Locally Advanced Pancreatic Cancer	0	5.92	01-09-2026
8	DCIS Margins and Genomic Profiles—Refresh Not Rehash!	0	5.93	01-09-2026
9	Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer	0	7.48	23-09-2026
10	Q&A: Combining diagnosis, staging, tumor localization and surgery into a minimally invasive procedure for lung cancer	0	6.9	02-09-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.96. Источник: archderm.jamanetwork.com.